Estrogen receptor (ER) expression, progesterone receptor (PR) expression, and human epidermal growth factor receptor-2 (HER2) overexpression or amplification are well-established biomarkers that drive treatment decisions for patients with breast cancers (BC)[1]. Here, ERBB2 is linked to breast cancer.